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AbstrAct
Objectives to perform a systematic literature review on 
imaging techniques for diagnosis, outcome prediction 
and disease monitoring in large vessel vasculitis (lVV) 
informing the european league against rheumatism 
recommendations for imaging in lVV.
Methods Systematic literature review (until 10 March 
2017) of diagnostic and prognostic studies enrolling >20 
patients and investigating ultrasound, Mri, ct or positron 
emission tomography (Pet) in patients with suspected 
and/or established primary lVV. Meta-analyses were 
conducted, whenever possible, obtaining pooled estimates 
for sensitivity and specificity by fitting random effects 
models.
Results Forty-three studies were included (39 on 
giant cell arteritis (gca), 4 on takayasu arteritis (taK)). 
Ultrasound (‘halo’ sign) at temporal arteries (8 studies, 
605 patients) and Mri of cranial arteries (6 studies, 509 
patients) yielded pooled sensitivities of 77% (95% ci 62% 
to 87%) and 73% (95% ci 57% to 85%), respectively, 
compared with a clinical diagnosis of gca. corresponding 
specificities were 96% (95% ci 85% to 99%) and 
88% (95% ci 81% to 92%). two studies (93 patients) 
investigating Pet for gca diagnosis reported sensitivities 
of 67%–77% and specificities of 66%–100% as compared 
with clinical diagnosis or temporal artery biopsy. in taK, 
one study each evaluated the role of magnetic resonance 
angiography and ct angiography for diagnostic purposes 
revealing both a sensitivity and specificity of 100%. 
Studies on outcome prediction and monitoring disease 
activity/damage were limited and mainly descriptive.
Conclusions Ultrasound and Mri provide a high 
diagnostic value for cranial gca. More data on the role of 
imaging for diagnosis of extracranial large vessel gca and 
taK, as well as for outcome prediction and monitoring in 
lVV are warranted.
InTROduCTIOn
Large vessel vasculitis (LVV) is the most 
common form of primary vasculitis 
comprising (cranial and large vessel (LV)) 
giant cell arteritis (GCA), Takayasu arteritis 
(TAK) and idiopathic aortitis. Prompt diag-
nosis and treatment of LVV are important 
to prevent serious ischaemic complica-
tions such as visual loss in GCA, vascular 
Key messages
What is already known about this subject?
 ► imaging modalities including ultrasound (US), Mri, 
ct and 18F-FDg positron emission tomography 
are frequently used for diagnosing large vessel 
vasculitis (lVV) in clinical practice. However, their 
diagnostic value is still questioned by several 
clinicians, especially by those with less experience 
in imaging.
What does this study add?
 ► US and Mri of the superficial temporal artery reveal 
a good performance for the diagnosis of cranial 
giant cell arteritis (gca) with pooled sensitivities 
of 77% and 73%, respectively, as well as pooled 
specificities of 96% and 88%, respectively.
 ► Studies on the diagnostic accuracy of imaging in 
extracranial large vessel gca and takayasu arteritis 
are scarce.
 ► Studies on the role of imaging techniques for 
outcome prediction and monitoring of disease 
activity and damage of lVV are limited and mainly 
non-informative because of heterogeneous study 
design and of being mostly descriptive, not enabling 
reaching an inferential conclusion.
How might this impact on clinical practice?
 ► the results of this systematic literature review 
help clinicians to place the use of imaging in the 
diagnosis of lVV in their daily clinical practice.
 ► US and Mri of the temporal arteries can be 
accurately used in the diagnostic work-up of 
patients with a suspicion of cranial gca, possibly 
avoiding the need for more invasive diagnostic 
techniques, such as a temporal biopsy.
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stenosis/occlusion in TAK and aneurysm formation 
in idiopathic aortitis.1 2 Temporal artery biopsy (TAB) 
has been the standard test to confirm the diagnosis of 
GCA3–5; although highly specific, biopsy is invasive and 
lacks sensitivity, with false-negative results in up to 61% of 
patients compared with a clinical diagnosis of GCA.6 In 
addition, extracranial arteries are usually not accessible 
for histological assessment, and in extracranial LV-GCA, 
temporal arteries are spared in up to 40% of patients.7 8 
Consequently, GCA diagnosis often relies on the combi-
nation of clinical symptoms, elevated serum inflamma-
tory markers and imaging findings.
The classification criteria for TAK focus on the detection 
of arterial stenosis and occlusions as detected by conven-
tional angiography.9 Conventional angiography, however, 
does not allow the delineation of vessel wall changes and 
bears the potential risk of complications, such as allergic 
reactions, haematoma, iatrogenic embolisation and arte-
rial dissection. Therefore, angiography is being increas-
ingly replaced by newer imaging modalities.2
Aortitis is common in GCA and TAK but rarely occurs 
as an isolated (idiopathic) disease.10 The diagnosis of 
idiopathic aortitis is frequently based on radiological 
findings with inflammatory wall changes of the aorta 
because histological assessment is only possible if aortic 
aneurysms are operated.11
The role of imaging modalities including ultrasound 
(US), MRI, CT and 18F-FDG positron emission tomog-
raphy (PET) in LVV has been addressed in several studies 
over the last years. Imaging modalities, however, are not 
yet uniformly used for the diagnosis and monitoring of 
LVV in clinical practice. A European League Against 
Rheumatism (EULAR) project has therefore been 
undertaken to develop recommendations for the use of 
imaging in LVV in clinical practice.12
The aim of this systematic literature review (SLR) was 
to summarise the available evidence on the performance 
of imaging techniques on diagnosis, outcome prediction 
and monitoring of disease activity and damage in LVV, as 
well as technical aspects of imaging modalities in order 




In the first meeting of the EULAR task force, four key 
questions were framed according to the Population, 
Intervention, Comparator, Outcome (PICO) format.13 
These referred to the role of US, MRI, magnetic reso-
nance angiography (MRA), PET±CT, CT or CT angiog-
raphy (CTA) in diagnosis, outcome prediction and moni-
toring of LVV, as well as technical aspects for the different 
imaging techniques (online supplementary table S1a–d). 
The population of interest consisted of adult patients 
(≥18 years) with a suspected (for diagnostic studies 
and studies on technical aspects) and/or established 
primary LVV (ie, GCA, TAK and idiopathic aortitis; for 
studies on monitoring, prognosis and technical aspects). 
For diagnostic accuracy of imaging, physician’s clinical 
diagnosis (both at first assessment and also at first and 
follow-up assessments) and TAB were accepted as refer-
ence standards, and sensitivity and specificity of imaging 
were the outcomes of interest. For prognostic and moni-
toring studies, presence and absence of baseline imaging 
abnormalities (or also over the follow-up for monitoring 
studies) were considered as ‘interventions’ and ‘compar-
ator’, respectively; outcomes of interest were those 
reflecting disease activity or damage. The task force did 
not specify these outcomes, because it was argued that 
the literature review would reveal relevant outcome 
parameters addressed in prospective studies.
Eligible studies were all full research articles of 
cohort studies with prospective design (excluding 
research letters, case–control and retrospective studies) 
involving >20 patients; both cross-sectional and longitu-
dinal studies were included.
study selection, data extraction and assessment of risk of 
bias (RoB)
The SLR was conducted by two reviewers (ChristinD and 
ChristiaD) under the guidance of the methodologist (SR) 
and with the help of the statistician (AS), who performed 
the meta-analyses. The search strategy was developed 
by an experienced librarian (LF) (online supplemen-
tary text S1). MEDLINE (1946), Embase (1974) and 
the Cochrane Library (1993) databases were searched 
without language restrictions from their inception dates 
(noted in parentheses) until 10 March 2017.
The reviewers screened independently all titles and 
abstracts to identify potentially eligible studies that were 
then reviewed in full text. Papers fulfilling the inclusion 
criteria were proceeded to data extraction. Both reviewers 
independently retrieved data using a predefined data 
extraction sheet. The following data were extracted for 
diagnostic studies: studies’ main characteristics (year of 
publication, setting, number of included patients, inclu-
sion criteria, use of glucocorticoids (GC) before perfor-
mance of imaging), patient characteristics (number 
(%) of females, patients’ age), disease characteristics 
(number (%) of patients fulfilling clinical criteria for 
GCA or TAK, number (%) of patients with positive TAB, 
number (%) of patients with the LV-GCA subset), tech-
nical aspects (imaging devices used, elementary lesions 
and structures investigated, blinding of the index test to 
reference standard), index test (lesions identified in the 
index test that are analysed), reference standard, diag-
nostic performance (raw data to calculate sensitivity, 
specificity, positive likelihood ratio (LR+) and negative 
likelihood ratio (LR−)) and parameters required for the 
assessment of the RoB. For prognostic and monitoring 
studies, the following items were retrieved: study’s aim, 
inclusion criteria, number of patients included, number 
(%) of patients with follow-up, period of follow-up, inves-
tigated structures, signs and time of change, prognostic 
factors and outcome—as explained above any outcome 
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reflecting disease activity or damage. For technical 
aspects, we extracted the study aim, number of included 
patients, inclusion criteria, number of patients finally 
diagnosed with GCA or TAK, investigated structures, 
different technical aspects being compared (interven-
tion and comparator) and outcome (diagnostic perfor-
mance or disease activity/damage, as appropriate) were 
detailed.
RoB of the studies was appraised independently by the 
same two reviewers who conducted the SLR. For studies 
on diagnostic accuracy, the Quality Assessment of Diag-
nostic Accuracy Studies-2 (QUADAS-2) tool was used 
comprising four domains: patient selection, index test, 
reference standard, as well as flow and timing. Each of 
these domains was evaluated as having a ‘low’, ‘high’ or 
‘unclear’ RoB, whereas concerns about applicability were 
evaluated in the first three domains also as ‘low’, ‘high’ 
or ‘unclear’. The Quality In Prognosis Studies (QUIPS) 
tool was applied for the assessment of prognostic studies 
evaluating the following aspects: study participation 
and attrition, prognostic factor measurement, outcome 
measurement, study confounding as well as statistical 
analysis/reporting.14 15 Each QUIPS domain was rated 
as ‘high’, ‘moderate’, ‘low’ or ‘unclear’ RoB. For studies 
on monitoring and technical aspects, no RoB assessment 
was performed, because identified studies were mainly 
only descriptive (see below), hence no adequate RoB 
assessment could be performed. Discrepancies between 
reviewers regarding study selection, data extraction 
and RoB assessment were solved by discussion. A third 
reviewer (WAS) was involved in case no consensus could 
be achieved (n=2 studies).
data analysis
Meta-analysis for diagnostic accuracy was performed 
whenever possible, that is, in case enough data stem-
ming from homogeneous studies concerning imaging 
modality, reference standard (either clinical diagnosis 
or TAB as reference standards) and outcome assessment 
was available. For all other diagnostic accuracy studies as 
well as for prognostic and monitoring studies, individual 
results (of studies not included in the meta-analysis) are 
reported.
Pooled sensitivity and specificity were estimated by 
random-effects bivariate generalised binomial mixed 
models. This is the recommended analytical method for 
meta-analysis of diagnostic tests, since it estimates sensi-
tivity and specificity together taking into account their 
correlation.16 Parameter estimates from each model were 
used to derive the LR+ and LR− and 95% CIs. In case of 
limited data (here: ≤3 studies), the above-mentioned rule 
was relaxed, and univariate random-effects models were 
used by assuming no correlation between sensitivity and 
specificity.16
Sensitivity analyses were performed for diagnostic accu-
racy studies on US and MRI in GCA evaluating the effect 
of: (1) the quality of studies (excluding those with high 
RoB), (2) GC treatment before the index test (including 
only those without GC treatment before imaging), 
(3) the use of imaging devices with high resolution 
(including only studies that used >12 MHz probes for US 
or 3T MRI machines), (4) target population (including 
only studies with a detailed description of what was meant 
by the ‘suspicion’ of GCA) and (5) reference standard 
(including only studies with clinical diagnosis confirmed 
after follow-up used as reference standard).
All analyses were conducted in Stata V.14. The Cochrane 
Collaboration’s Review Manager Software V.5.3 was used 
to build forest plots.
ResuLTs
Out of 8691 articles screened, 43 studies were finally 
included with some of these addressing more than 
one index test or key objectives (see flow chart in 
online supplementary figure S1). For GCA, 27 arti-
cles focused on the diagnostic accuracy,6 17–425 studies 
on outcome prediction,43–47 13 on monitoring disease 
activity17 20 22 25 28 29 43–45 48–51 and five on technical 
aspects.35 37 52–54 For TAK, four studies were included 
with two studies addressing diagnostic accuracy55 56 and 
two studies evaluating the value of imaging for moni-
toring.57 58 No study on isolated aortitis was identified.
diagnostic accuracy studies
For GCA, most diagnostic accuracy studies focused on 
the role of US (n=17)6 17–32 or MRI (n=8).33–40 One study 
addressed the role of PET,41 and another study examined 
the role of PET and CTA for GCA diagnosis.42 In TAK, 
one study evaluated the role of MRA and another the 
role of CTA.55 56
Ultrasound
The main study—and patient—characteristics are 
summarised in table 1 with additional data and details 
on the RoB assessment described in online supplemen-
tary tables S2 and S6, respectively. Most US studies in 
GCA tested the ‘halo’ sign (n=166 17–31) as a key elemen-
tary lesion defining vasculitis. Other US signs addressed 
(mostly in combination with the ‘halo’ sign) were stenosis 
(n=136 17 18 20 22–30), occlusion (n=96 17 22–26 28 30) and the 
‘compression’ sign (n=230 32).
Results of the meta-analysis on the diagnostic perfor-
mance of the different US signs are summarised in 
table 2, and results of individual studies are shown in 
figure 1A,B.
Eight studies (n=605, three studies with low 
RoB)17 19 20 23 25 28 30 31 investigated the value of the ‘halo’ 
sign in comparison with the clinical diagnosis of cranial 
GCA yielding a pooled sensitivity of 77% (95% CI 62% 
to 87%) and a specificity of 96% (95% CI 85% to 99%). 
A similarly good diagnostic performance was obtained 
when the ‘halo’ sign was compared with TAB as refer-
ence standard (seven studies, n=289, no study with low 
RoB).17–21 23 27 Also, the evaluation of the combination of 
US signs defining vasculitis (‘halo’, stenosis or occlusion) 
in comparison with clinical diagnosis (three studies, 
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n=560, no study with low RoB)6 17 22 or TAB (five studies, 
n=611, one study with low RoB)6 17 22–24 resulted in a 
similar diagnostic performance as the ‘halo’ sign alone. 
Sensitivity analyses for the diagnostic performance of the 
‘halo’ sign (compared with clinical diagnosis of cranial 
GCA) as detailed above, revealed higher pooled sensitiv-
ities (86%–89%) than the main analysis and comparable 
or slightly lower specificities. The only exception was the 
analysis including only studies without GC treatment 
before the index test, which had a slightly lower sensi-
tivity of 73% (table 3).
Two studies (n=140, both with low RoB),30 32 conducted 
by the same research group, investigated the ‘compres-
sion’ sign. The authors reported sensitivities of 
77%–79% and a specificity of 100% of this sign compared 
with the clinical diagnosis of cranial GCA.
In three US studies6 29 31 (n=541, one study with low 
RoB), extracranial arteries were examined. Only one of 
these addressed the effect of the examination of temporal 
plus axillary arteries on the diagnostic performance 
as compared with the assessment of temporal arteries 
alone. This study revealed an incremental change of 
sensitivity of 2% by the former compared with the latter 
approach.31 Although 22 arteries were evaluated in the 
study by Aschwanden et al29 a low sensitivity of 55% was 
observed for US (‘halo’ and stenosis) to detect vasculitis. 
No separate results for the diagnostic performance of US 
in patients with cranial and extracranial LV involvement 
were provided in that study.29
No study on US in TAK was identified.
Magnetic resonance imaging
All MRI studies addressed vessel wall thickening and 
contrast enhancement as signs of vasculitis in the superfi-
cial temporal and occipital arteries. Study characteristics 
are detailed in table 4, individual sensitivity and speci-
ficity data are reported in online supplementary table S3 
and figure 1A,B and details of the RoB assessment are 
shown in online supplementary table S6.
Six MRI studies were included in the meta-analysis 
using clinical diagnosis33–35 38–40 (n=509, one with low 
RoB) and/or TAB33–35 37 38 40 (n=443, one with low RoB) 
as the reference standard (table 2). A pooled sensitivity 
of 73% (95% CI 57 to 85) and specificity of 88% (95% 
CI 81 to 92) was found comparing MRI with the clin-
ical diagnosis of cranial GCA. When TAB was used as 
the reference standard, MRI yielded a sensitivity of 93% 
(95% CI 89 to 96) and a specificity of 81% (95% CI 73 
to 87). Sensitivity analyses, as detailed in table 3, under-
lined the robustness of the main analysis. Of note, in all 
included MRI studies, patients were on treatment with 
GCs when the MRI was conducted. One study examined 
the role of the deep temporal arteries and the involve-
ment of the temporal muscle for the diagnosis of GCA 
revealing a sensitivity of 42% and a specificity of 90% 
(online supplementary table S3).36 This study was not 
included in the meta-analysis because the structures 
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No study was identified addressing the role of MRI for 
the evaluation of extracranial LV-GCA.
One study55 (n=30, low RoB) investigated MRA for the 
diagnosis of TAK using conventional angiography as the 
reference standard (see table 4 and online supplemen-
tary tables S3 and S6 for further details). A sensitivity of 
100% (95% CI 76 to 100) and a specificity of 100% (95% 
CI 63 to 100) for MRA was reported.
18F-FDg positron emission tomography
Only two studies41 42 (n=93, one study with low RoB42) 
focused on the diagnostic performance of 18F-FDG-PET 
for the diagnosis of extracranial LV-GCA yielding sensi-
tivities of 67%–77% and specificities of 66%–100%, using 
TAB or a clinical diagnosis after 6 months as reference 
standards, respectively. The study by Lariviere et al42 
(n=24, low RoB), reporting a specificity of 100%, applied 
a semiquantitative approach (aortic-to-blood pool uptake 
ratio) for the evaluation of 18F-FDG vessel wall uptake 
(table 5 and online supplementary table S4 for further 
study details, online supplementary table S6 for RoB 
assessment).
ct angiography
The study by Lariviere et al mentioned above42 (n=25, 
with low RoB) evaluated the roles of PET and CTA within 
the same population. CTA revealed a sensitivity of 73% 
(95% CI 45 to 92) and a specificity of 78% (95% CI 40 to 
97) using the clinical diagnosis of GCA after 6 months as 
reference standard.
For the diagnosis of TAK, one study56 (n=25, with low 
RoB) examined the role of CTA reporting a sensitivity 
of 100% (95% CI 76 to 100) and a specificity of 100% 
(95% CI 40 to 100) compared with conventional angi-
ography (table 5 and online supplementary tables S5 for 
further study details, online supplementary table S6 for 
RoB assessment).
Outcome prediction, monitoring disease activity and damage 
and technical aspects of imaging techniques
Description of observations without inferences in moni-
toring studies (n=11) and studies on technical aspects 
(n=5) as well as heterogeneity in study design, outcomes 
and technical settings of prognostic studies (n=5) 
precluded any meta-analysis. Main study characteristics 
and findings are summarised in online supplementary 
tables S7–S10.
Five studies investigated the role of US,43 44 
18F-FDG-PET45 46 or CT47 for outcome prediction in GCA 
(online supplementary table S7) with none of them 
being appraised at low RoB (online supplementary table 
S8). GCA characteristic US lesions at baseline did not 
predict a relapse,44 and the risk of ischaemic complica-
tions was similar in patients with temporal and extracra-
nial LV involvement.43 The response of 18F-FDG-uptake 
to GC therapy (at 3 and 6 months) was not associated 
with the risk of relapse45; however, baseline 18F-FDG-up-
take at the aorta predicted aortic dilatation during long-
term disease course according to one study.46 For TAK, 
no study was identified addressing the role of imaging for 
outcome prediction.
For GCA, 13 studies were found investigating the 
role of imaging for monitoring disease activity and 
damage.17 20 22 25 28 29 43–45 48–51 Ten US studies (197 
patients, follow-up range: 1–41 months) reported 
that the ‘halo’ sign at temporal arteries was no longer 
detected in the majority of patients after 2–4 weeks of GC 
therapy,17 20 22 25 28 29 43 44 48 49 whereas at larger arteries, 
vessel wall swelling persisted in two thirds of patients 
according to CT and US studies.43 51 Additionally, the 
occurrence of new vasculitic US lesions was reported in 
up to 10% of GCA patients despite GC treatment.43 18F-
FDG uptake in the wall of extracranial LVs was compa-
rable in GCA patients in full remission and those with 
a relapse.45 In TAK, US and MRI were also not helpful 
Figure 1 (A) Diagnostic performance of different ultrasound 
(US) signs of vasculitis and MRI studies in comparison with 
clinical diagnosis as reference standard. (B) Diagnostic 
performance of different US signs of vasculitis and MRI 
studies in comparison with temporal artery biopsy as 
reference standard. TP, true positives; FP, false positives; FN, 
false negatives; TN, true negatives.
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to discriminate between active disease and remission57 58 
(see online supplementary table S9 for details on moni-
toring studies).
All five studies (two on MRI, three on 
18F-FDG-PET)35 37 52–54 on technical requirements, 
settings and operational procedures were performed in 
GCA patients and are summarised in online supplemen-
tary table S10.
dIsCussIOn
This SLR confirms the good performance of US and MRI 
for the diagnosis of cranial GCA. The ‘halo’ sign (US) 
and increased vessel wall thickness in combination with 
contrast enhancement (MRI) of superficial temporal 
arteries, respectively, were the most relevant imaging 
findings suggesting GCA. Data on imaging for diagnosis 
of extracranial LV disease remain limited.
The diagnostic performance of US was better in the 
current than in previous meta-analyses with a higher 
sensitivity (77% vs 55%–69%)59–61 but similar specificity 
(96% vs 89%–94%)59–61 for diagnosis of cranial GCA, 
which possibly relies on the fact that we included more 
recent, high-quality studies. A recent SLR conducted 
by Buttgereit et al identified many of the same studies 
described in this work; however, that SLR focused on 
imaging modalities in GCA and PMR (omitting papers 
on TAK), spared CT and only reported diagnostic values 
of individual studies rather than providing meta-analysed 
estimates on sensitivity and specificity.62 This is a clear 
addition of our SLR, together with also covering outcome 
prediction as well as monitoring disease activity/damage, 
not addressed in previous SLRs. The sensitivity analyses 
of the meta-analysis suggest that technical aspects and 
the definition of study entry criteria have all an impact 
on the sensitivity of US. Expertise with vascular US (as 
in any other diagnostic test) is another factor that may 
influence its diagnostic properties. We could not assess 
this factor, since all studies were conducted by expert 
groups. GC treatment before an imaging test has been 
demonstrated to reduce the sensitivity of the respec-
tive imaging modality.6 63 Our results do not seem to 
confirm this observation since the ‘halo’ was less sensi-
tive for diagnosis of cranial GCA when pooling studies 
in which patients had not been treated with GCs before 
US was performed as compared with the main analysis. 
This finding, however, was largely influenced by a single 
Table 3 Sensitivity analyses for diagnostic studies on ultrasound (‘halo’ sign) and MRI in comparison with clinical diagnosis 












  Halo versus clinical 
diagnosis (main analysis)*
605 (eight 
studies)17 19 20 23 25 28 30 31
19 (4.8 to 75.5) 0.2 (0.1 to 0.4) 77 (62 to 87) 96 (85 to 99)
   Excluding high RoB 
studies*†
255 (four studies)25 28 30 31 16 (7.3 to 35.2) 0.2 (0.1 to 0.3) 86 (76 to 93) 95 (89 to 98)
   Studies without GC* 156 (four studies)19 20 25 28 4.0 (2.6 to 6.2) 0.3 (0.2 to 0.7) 73 (49 to 89) 82 (75 to 87)
   Studies with high 
resolution device*‡
292 (four studies)19 25 30 31 13.8 (3.9 to 48.2) 0.1 (0.1 to 0.3) 87 (77 to 93) 94 (79 to 98)
   Suspected diagnosis 
well-defined§
175 (three studies)25 28 31 11.5 (4.5 to 29.2) 0.1 (0.1 to 0.3) 89 (76 to 95) 92 (83 to 97)
   Longitudinal studies§ 244 (four studies)19 25 28 31 7.5 (3.4 to 16.8) 0.1 (0.1 to 0.3) 88 (77 to 94) 88 (78 to 94)
MRI
  MRI versus clinical 
diagnosis (main analysis)*
509 (six studies)33–35 38–40 5.9 (3.4 to 10.3) 0.3 (0.2 to 0.5) 73 (57 to 85) 88 (81 to 92)
   Excluding high RoB 
studies*† 
446 (five studies)33 34 38–40 6.8 (3.6 to 13) 0.3 (0.1 to 0.6) 75 (56 to 88) 89 (82 to 93)
   Studies with high 
resolution device*‡ 
260 (four studies)33 35 39 40 3.8 (2 to 7.5) 0.4 (0.2 to 0.8) 68 (44 to 85) 82 (69 to 91)
   Suspected diagnosis§ 270 (three studies)33 34 38 8.7 (5 to 15.2) 0.2 (0.1 to 0.3) 82 (74 to 87) 91 (84 to 95)
   Longitudinal studies§ 411 (three studies)34 38 40 7.5 (4.9 to 11.7) 0.3 (0.2 to 0.4) 75 (65 to 84) 90 (85 to 93)
*Bivariate random-effects binomial generalised mixed model.
†High RoB was defined, in the case of concern on ≥5 RoB items or all 3/3 applicability items out of the QUADAS-2 tool.
‡High resolution devices were defined as >12 MHz probes for ultrasound or 3T MRI machines.
§Univariate random-effects models.
longitudinal studies, studies with clinical diagnosis after follow-up as reference standard; LR, likelihood ratio; QUADAS-2, Quality 
Assessment of Diagnostic Accuracy Studies-2; RoB, risk of bias; suspected diagnosis, studies with detailed definition of suspicion of giant 
cell arteritis included; without GC, studies without glucocorticoid treatment before performance of ultrasound. 
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study with high RoB and, by exclusion of that particular 
study, US was more sensitive to diagnose cranial GCA in 
patients without GCs as compared with the main analysis 
(83% vs 77%).
The observation that the combination of the US signs 
‘halo’, stenosis and occlusion had a similar sensitivity to 
the ‘halo’ sign alone can be explained by the fact that in 
GCA, vascular stenosis or occlusion is usually caused by 
inflammatory wall swelling, which is the morphological 
correlate of the ‘halo’ sign.6 17 22–24
The ‘compression’ sign, another key elementary 
US lesion for cranial GCA, revealed a good diagnostic 
performance in two studies.30 32 Both studies, however, 
were published by the same research group and were not 
completely independent since five patients (Aschwanden 
M, personal communication) were included in both 
studies.
The pooled sensitivity (73%) and specificity (88%) of 
MRI was lower than that of US (77% and 96%, respec-
tively) when the clinical diagnosis was used as the refer-
ence standard, while MRI had a higher sensitivity (93% 
vs 70%) and a similar specificity (81% vs 84%) to sonog-
raphy when both modalities were compared with TAB. 
This indirect comparison must be interpreted with 
caution, because the different test performances are 
likely also influenced by variations in study design and 
data analysis. In most MRI studies, for example, TAB was 
performed in selected cases with high suspicion of GCA 
only, while in US studies, the majority of patients under-
went a TAB. A retrospective study comparing US and 
MRI directly reported a similar sensitivity (69% and 67%, 
respectively) and specificity (both with 91%) for both 
techniques,64 whereas a prospective direct comparison of 
both modalities is still missing.
Although PET is commonly used in patients with 
suspected extracranial LVV, fever of unknown origin 
or other systemic illnesses, the SLR identified only 
two prospective studies on this imaging modality41 42 
reporting highly discordant results: in the study of Block-
mans et al, data from patients with TAB proven GCA, and 
PMR with 18F-FDG uptake in LVs were both considered as 
GCA cases. This creates ‘ground’ for circular reasoning 
given that the test under investigation had also been 
part of the reference standard.41 Recalculating the PET 
data for TAB positive GCA patients yielded a sensitivity 
of 77% and specificity of 66%, which might be an under-
estimation of the true diagnostic value of PET, because 
TAB is frequently false negative in patients with extracra-
nial LV-GCA.7 Besides, the study by Lariviere et al, which 
applied the clinical diagnosis after follow-up of 6 months 
as reference standard, showed a specificity of PET of 
100%.42 This divergence underlines that the perfor-
mance of a diagnostic test is strongly influenced by the 
reference standard and that such a standard is urgently 
needed for extracranial LVV in order to facilitate future 
studies in the field.
Extracranial large arteries are involved in up to 80% 
of patients with GCA.8 48 65 66 In one US study, sensitivity 
improved by only 2%, when axillary arteries were inves-
tigated in addition to temporal arteries, with similar 
specificity.31 Since no other studies were available, the 
diagnostic gain of evaluating different vascular beds with 
imaging in addition to cranial arteries remains there-
fore unclear. Additional studies are warranted to clarify 
whether a standardised hierarchical approach to assess 
different vascular territories (eg, temporal, carotid, 
subclavian and axillary arteries) with US or other imaging 
modalities improves the diagnostic certainty of cranial 
and extracranial LV-GCA to an extent that justifies the 
increased clinical effort. The relatively low sensitivity of 
55% for US assessment of 22 arteries reported in the 
study by Aschwanden et al is probably explained by the 
fact that one-third of patients had extracranial LV-GCA 
and that the American College of Rheumatology (ACR) 
criteria were applied as the reference standard. The ACR 
criteria mainly capture patients with cranial GCA.29
In TAK, both studies on MRA and CTA revealed excel-
lent sensitivities and specificities using conventional 
angiography as the reference standard. These studies, 
however, were small, included (partially) the same 
patients and there was a long interval between MRA/
CTA and angiography.55 56 Future studies on the diag-
nostic performance of imaging techniques in TAK are 
thus warranted, and there is a need for a novel reference 
standard, given that conventional angiography is highly 
invasive.
Current evidence on the role for imaging modali-
ties for outcome prediction, as well as for monitoring 
disease activity and damage in LVV is limited. Although 
a response of vessel wall alterations to GC treatment was 
detected in both, cranial and extracranial LV-GCA and 
TAK,17 20 22 25 28 29 43–45 48–51 57 58 neither imaging findings at 
baseline nor during follow-up were clearly associated with a 
disease relapse or any other outcome. Besides, monitoring 
studies were mainly descriptive and without clear infer-
ences, thus precluding drawing a clear conclusion from 
them that could be of further information for an SLR like 
ours. The decision to include these studies in the current 
SLR was solely based on content knowledge, while from 
a methodological point of view, this decision is obviously 
arguable. Now, 15 studies on monitoring are included 
in this SLR, as we were inclusive, and facing a scarcity of 
studies, tried to retrieve from the literature any informa-
tion on the value of imaging for monitoring LVV. However, 
we could have also been somewhat more restrictive by only 
including studies that analysed any association between the 
imaging for monitoring and other outcomes (eg, relapse); 
if this was the case, no eligible study would have been found 
in the literature. The development of standard tools for 
monitoring disease activity and damage in LVV is urgently 
needed and might facilitate further research on the eval-
uation of the role of imaging for disease monitoring and 
outcome prediction.
Studies on minimal technical requirements, settings 
and operational procedures for the evaluation of patients 
with cranial and extracranial LV-GCA are also scarce. 
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The quality of imaging devices is obviously a critical issue, 
because poor equipment may easily lead to misclassifica-
tion of patients67 and because heterogeneity in the quality 
of imaging devices renders comparison between studies 
difficult. To avoid this type of bias in our meta-analysis, we 
performed a sensitivity analysis focusing on studies using 
high-quality US machines only which resulted, as expected, 
in a higher sensitivity as compared with the main analysis 
(87% vs 77%), thus confirming the important role of using 
high-quality imaging devices.
In summary, this SLR confirms the good performance of 
US and MRI of the superficial temporal arteries for diag-
nosis of cranial GCA. More data on imaging techniques 
in LV-GCA and TAK are needed, as well as on the role of 
imaging for outcome prediction, monitoring and technical 
aspects of LVV, as current studies on these aspects are not 
conclusive. Based on the results of this SLR, EULAR recom-
mendations for the use of imaging modalities in LVV in 
daily clinical practice have been developed.
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